OBJECTIVE: To examine the feasibility and significance of <sup>13</sup>C-Hiolein breath test in evaluating chronicpancreatitis-related exocrine insufficiency and efficacy of enzyme treatment.METHODS: The &...OBJECTIVE: To examine the feasibility and significance of <sup>13</sup>C-Hiolein breath test in evaluating chronicpancreatitis-related exocrine insufficiency and efficacy of enzyme treatment.METHODS: The <sup>13</sup>C-Hiolein breath test was used in 8 healthy volunteers （group 1）, 8 chronicpancreatitis （CP） patients without steatorrhea （group 2）, and 8 CP patients with steatorrhea （group 3）.To evaluate the function of pancreatic exocrine, <sup>13</sup>CO<sub>2</sub> was determined following <sup>13</sup>C-Hiolein diet. The<sup>13</sup>C-Hiolein test was repeated in group 3 after enzyme supplement therapy.RESULTS: Administration of <sup>13</sup>C-Hiolein diet resulted in significantly higher cumulative percent dose of<sup>13</sup>C recovery per 6 h （cPDR/6 h） and maximal PDR (PDR<sub>peak</sub>) in the healthy controls （group 1） thanthe CP patients with steatorrhea （group 3） （11.22%±1.22% and 6.11%±0.59% vs. 2.87%±0.73%and 1.53%±0.36%, respectively, both P【0.01）. In the CP patients with steatorrhea （group 3）, arepeated test after enzyme supplementation therapy showed a significant elevation of both cPDR/6 h andPDR<sub>peak</sub> （9.03%±0.84% and 2.33%±0.47%, both P【0.01 compared with those before enzymetreatment）, but cPDR/6 h remained significantly lower than that in the healthy volunteers （group 1, P【0.05）. Both cPDR and PDR<sub>peak</sub> in the CP patients without steatorrhea （group 2） were similar to those inthe healthy controls （group 1, both P】0.05）.CONCLUSION: The results of <sup>13</sup>C-Hiolein breath test well reflect fat metabolism status in CP patients,and the test can be used to monitor the efficacy of pancreatic enzymes therapy.展开更多
文摘OBJECTIVE: To examine the feasibility and significance of <sup>13</sup>C-Hiolein breath test in evaluating chronicpancreatitis-related exocrine insufficiency and efficacy of enzyme treatment.METHODS: The <sup>13</sup>C-Hiolein breath test was used in 8 healthy volunteers （group 1）, 8 chronicpancreatitis （CP） patients without steatorrhea （group 2）, and 8 CP patients with steatorrhea （group 3）.To evaluate the function of pancreatic exocrine, <sup>13</sup>CO<sub>2</sub> was determined following <sup>13</sup>C-Hiolein diet. The<sup>13</sup>C-Hiolein test was repeated in group 3 after enzyme supplement therapy.RESULTS: Administration of <sup>13</sup>C-Hiolein diet resulted in significantly higher cumulative percent dose of<sup>13</sup>C recovery per 6 h （cPDR/6 h） and maximal PDR (PDR<sub>peak</sub>) in the healthy controls （group 1） thanthe CP patients with steatorrhea （group 3） （11.22%±1.22% and 6.11%±0.59% vs. 2.87%±0.73%and 1.53%±0.36%, respectively, both P【0.01）. In the CP patients with steatorrhea （group 3）, arepeated test after enzyme supplementation therapy showed a significant elevation of both cPDR/6 h andPDR<sub>peak</sub> （9.03%±0.84% and 2.33%±0.47%, both P【0.01 compared with those before enzymetreatment）, but cPDR/6 h remained significantly lower than that in the healthy volunteers （group 1, P【0.05）. Both cPDR and PDR<sub>peak</sub> in the CP patients without steatorrhea （group 2） were similar to those inthe healthy controls （group 1, both P】0.05）.CONCLUSION: The results of <sup>13</sup>C-Hiolein breath test well reflect fat metabolism status in CP patients,and the test can be used to monitor the efficacy of pancreatic enzymes therapy.
